Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Working Capital Changes (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Other Working Capital Changes for 7 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 101.65% to $10.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was $6.2 million, a 1257.08% increase, with the full-year FY2025 number at $6.2 million, up 1257.08% from a year prior.
  • Other Working Capital Changes was $10.5 million for Q4 2025 at Nurix Therapeutics, up from -$7.3 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $50.8 million in Q4 2023 to a low of -$28.2 million in Q3 2023.
  • A 5-year average of $250800.0 and a median of -$952500.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: soared 1373.83% in 2021, then tumbled 350.02% in 2025.
  • Nurix Therapeutics' Other Working Capital Changes stood at $7.9 million in 2021, then crashed by 154.39% to -$4.3 million in 2022, then skyrocketed by 1287.02% to $50.8 million in 2023, then tumbled by 89.72% to $5.2 million in 2024, then surged by 101.65% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Other Working Capital Changes are $10.5 million (Q4 2025), -$7.3 million (Q3 2025), and $4.6 million (Q2 2025).